EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
86.24
+2.63 (+3.15%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close83.61
Open84.02
Bid85.29 x 800
Ask86.44 x 1000
Day's Range84.01 - 86.79
52 Week Range53.06 - 123.99
Volume2041616
Avg. Volume2,226,520
Market Cap13B
Beta (3Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors
    PR Newswire

    Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors

    Exact Sciences Corp. (NASDAQ: EXAS) today announced Dr. David Ahlquist, co-inventor of Cologuard® and emeritus professor of medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, has been named a Fellow of the National Academy of Inventors (NAI). Ahlquist's work has helped more than 3 million people get screened noninvasively for colorectal cancer with Cologuard.

  • Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company
    PR Newswire

    Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

    MADISON, Wisconsin, Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy, chairman and CEO of Exact Sciences. "We're excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along their cancer journey.

  • Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation
    PR Newswire

    Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation

    Data to be Presented at AASLD 2019, Abstract Selected for The Best of the Liver Meeting® BOSTON , Nov. 8, 2019 /PRNewswire/ -- (NASDAQ: EXAS)  –  A new study of 443 patients by Exact Sciences Corp. and ...

  • PR Newswire

    Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences

    REDWOOD CITY, Calif., Nov. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (EXAS) at a special meeting held earlier today. As previously announced, on July 29, 2019, Genomic Health and Exact Sciences entered into the merger agreement by which Exact Sciences will acquire Genomic Health in a cash and stock transaction. With the receipt of the required stockholder approval, Genomic Health and Exact Sciences expect to close the transaction on Friday, November 8 subject to satisfaction of the remaining customary closing conditions.

  • PR Newswire

    Shenandoah Telecommunications Set to Join S&P SmallCap 600

    NEW YORK , Nov. 4, 2019 /PRNewswire/ -- Shenandoah Telecommunications Co. (NASD: SHEN) will replace Genomic Health Inc. (NASD: GHDX) in the S&P SmallCap 600 effective prior to the open of trading on Friday, ...

  • Exact Sciences to participate in November investor conferences
    PR Newswire

    Exact Sciences to participate in November investor conferences

    MADISON, Wis., Nov. 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million
    PR Newswire

    Exact Sciences reports third-quarter revenue growth of 85 percent to $219 million

    MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company generated revenue of $218.8 million and screened approximately 456,000 people with Cologuard during the quarter ended September 30, 2019. "The Exact Sciences team delivered another strong quarter and most importantly, has screened more than 3 million people with Cologuard over the last 5 years," said Kevin Conroy, chairman and CEO of Exact Sciences.

  • Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study
    PR Newswire

    Exact Sciences Presents New Stool-Based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study

    MADISON, Wis., Oct. 29, 2019 /PRNewswire/ -- (EXAS) – Promising research from Exact Sciences Corp. and Mayo Clinic shows new methylation and protein markers detect colorectal cancer and advanced adenomas with high accuracy. Findings from the blinded, case-control study were presented at the American College of Gastroenterology's (ACG) 2019 Annual Scientific Meeting today. The study is part of an effort to increase specificity of Cologuard®, while maintaining its high level of sensitivity.

  • Moore Kuehn, PLLC Encourages Genomic Health, Inc. and Carbonite, Inc. Investors to Contact Firm
    PR Newswire

    Moore Kuehn, PLLC Encourages Genomic Health, Inc. and Carbonite, Inc. Investors to Contact Firm

    NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers ...

  • Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®
    PR Newswire

    Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®

    MADISON, Wis., Oct. 14, 2019 /PRNewswire/ -- (EXAS) – Exact Sciences Corp. today announced that, in collaboration with Mayo Clinic, it has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, incidence, and mortality rates. Voyage is a prospective, observational study designed to enroll more than 150,000 people with a valid Cologuard order and follow them for at least seven years to evaluate clinical outcomes. Voyage is one of the largest prospective, observational colorectal cancer screening studies ever conducted.

  • Exact Sciences schedules third-quarter 2019 earnings call
    PR Newswire

    Exact Sciences schedules third-quarter 2019 earnings call

    MADISON, Wis., Oct. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its third-quarter 2019 financial results after the close of the U.S. financial markets on Oct. 29, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally.

  • Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49
    PR Newswire

    Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49

    Stool DNA test offers a sensitive, noninvasive, at-home option to screen for colorectal cancer, second deadliest cancer in U.S. MADISON, Wis., Sept. 23, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) announced today that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, Cologuard, for eligible average-risk individuals ages 45 and older, expanding on its previous indication for ages 50 and older. Between 2004 and 2015, health care providers diagnosed more than 130,000 cases of colorectal cancer in Americans under age 50.i Among these cases, more than half were diagnosed at an advanced stage, stage III or stage IV, when survival rates are low.

  • Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE
    PR Newswire

    Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE

    MADISON, Wis., Sept. 19, 2019 /PRNewswire/ -- Exact Sciences is a member of the 2019 Best Workplaces for Women list, an honor given by Great Place to Work® and FORTUNE to employers providing supportive, inclusive workplaces. To determine the Best Workplaces for Women, Great Place to Work® analyzed anonymous survey feedback representing more than 4.6 million employees at Great Place to Work-CertifiedTM organizations. "Our work to deliver life-changing innovations in earlier cancer detection relies on a heavily engaged team," said Sarah Condella, senior vice president of Human Resources at Exact Sciences.

  • Cologuard® Helps More People Get Screened In A Cost-Effective Way
    PR Newswire

    Cologuard® Helps More People Get Screened In A Cost-Effective Way

    MADISON, Wis., Sept. 10, 2019 /PRNewswire/ -- (EXAS) -- Exact Sciences announced today that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA approval with half of those tested being previously unscreened.  Not only is Cologuard increasing the number of screened Americans, peer reviewed data shows that Cologuard is a cost-effective alternative for people at average risk for colorectal cancer (CRC). Data conclusively shows that screening reduces colorectal cancer incidence and mortality.  However, for over a decade, 1 out of every 3 Americans eligible for screening under current guidelines has gone unscreened, leading to colorectal cancer incidence and mortality rates that are higher than they should be.  Cologuard is an innovative, stool-based DNA test that was created to help improve the nation's stagnant screening rate.

  • Exact Sciences to participate in September investor conference
    PR Newswire

    Exact Sciences to participate in September investor conference

    MADISON, Wis., Aug. 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX
    PR Newswire

    GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX

    NEW ORLEANS , Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...

  • Exact Sciences to participate in August investor conference
    PR Newswire

    Exact Sciences to participate in August investor conference

    MADISON, Wis., Aug. 2, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.
    PR Newswire

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

    NEW YORK , July 29, 2019 /PRNewswire/ --  WeissLaw LLP   is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic ...

  • GlobeNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders

    NEW YORK, July 29, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Genomic Health, Inc. (“Genomic.

  • PR Newswire

    Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000

    - Company separately announces a definitive agreement to combine with Genomic Health, Inc. MADISON, Wis., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company generated revenue of $199.9 million and screened approximately 415,000 people with Cologuard during the quarter ended June 30, 2019. "The Exact Sciences team delivered another strong quarter, bringing us closer to our goal of capturing at least 40-percent share of the U.S. colorectal cancer screening market with Cologuard, from about 6 percent today," said Kevin Conroy, chairman and CEO of Exact Sciences.

  • Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company
    PR Newswire

    Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company

    MADISON, Wis. and REDWOOD CITY, Calif., July 29, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) and Genomic Health, Inc. (GHDX) today announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion. Together, Exact Sciences and Genomic Health will create a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest growing brands in cancer diagnostics, Cologuard and Oncotype DX, providing a robust platform for continued growth.

  • Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019
    PR Newswire

    Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019

    MADISON, Wis., July 17, 2019 /PRNewswire/ -- The more than 2,400 people of Exact Sciences work every day to create life-changing innovations in earlier cancer detection. Today, Exact Sciences announced that it is now Great Place to Work-Certified™. This certification is a significant achievement.

  • Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls
    PR Newswire

    Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls

    MADISON, Wis., July 9, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results. The company plans to release its second-quarter 2019 financial results after the close of the U.S. financial markets on July 30, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.